These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33039456)

  • 1. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model.
    Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F
    Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
    Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
    Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma.
    Liu S; Li M; Sun F; Zhang J; Liu F
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):901-912. PubMed ID: 36030435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.
    Liu S; Liu F; Zhao M; Zhang J
    Cancer Manag Res; 2020; 12():11803-11812. PubMed ID: 33239914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
    Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1.
    Valyi-Nagy K; Folberg R; Valyi-Nagy T; Maniotis AJ
    Exp Eye Res; 2007 May; 84(5):991-1000. PubMed ID: 17386925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.
    Tilgase A; Grīne L; Blāķe I; Borodušķis M; Rasa A; Alberts P
    BMC Res Notes; 2020 Apr; 13(1):222. PubMed ID: 32299493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.
    Kines RC; Varsavsky I; Choudhary S; Bhattacharya D; Spring S; McLaughlin R; Kang SJ; Grossniklaus HE; Vavvas D; Monks S; MacDougall JR; de Los Pinos E; Schiller JT
    Mol Cancer Ther; 2018 Feb; 17(2):565-574. PubMed ID: 29242243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures.
    Valyi-Nagy K; Dosa S; Kovacs SK; Bacsa S; Voros A; Shukla D; Folberg R; Valyi-Nagy T
    Cancer Gene Ther; 2010 Apr; 17(4):223-34. PubMed ID: 19893596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
    Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.
    Reale A; Gatta A; Shaik AKB; Shallak M; Chiaravalli AM; Cerati M; Zaccaria M; La Rosa S; Calistri A; Accolla RS; Forlani G
    J Transl Med; 2024 Sep; 22(1):862. PubMed ID: 39334370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.
    Liu S; Song W; Liu F; Zhang J; Zhu S
    Exp Eye Res; 2018 Jul; 172():144-151. PubMed ID: 29660328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer.
    Hu Z; Li Y; Yang J; Liu J; Zhou H; Sun C; Tian C; Zhu C; Shao M; Wang S; Wei L; Liu M; Li S; Wang J; Xu H; Zhu W; Li X; Li J
    Sci Rep; 2024 Oct; 14(1):23671. PubMed ID: 39389985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications.
    Alwithenani A; Taha Z; Thomson M; Chen A; Wong B; Arulanandam R; Diallo JS
    Front Immunol; 2023; 14():1332929. PubMed ID: 38169670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.